Search Results 1081-1090 of 16422 for monoclonal antibody
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Based on their findings, the research team is proceeding with a phase II clinical trial of the GM-CSF blocking antibody during CAR-T cell therapy. If the trial ...
Patients who are newly diagnosed with lymphoma are offered a combination of chemotherapy and antibody-based treatments. But for those who do not respond to ...
Treatment with an investigational drug or device within 30 days of study entry or any prior exposure to a monoclonal antibody targeting the CGRP pathway.
Known hypersensitivity to platinum, paclitaxel, another monoclonal antibody, or any of the excipients that cannot be controlled with standard measures (e.g., ...
... antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma. Participation eligibility.
... monoclonal antibody (mAb) therapy within 45 days prior to study Day 1. Note: Patients are allowed to receive any of the following treatments up to 7 days ...
Monoclonal antibody drugs · Mort Crim and Cancer · Mouth sores caused by cancer treatment: How to cope · MRI · Muscle pain · Needle biopsy · Night sweats · No ...
Immune globulin contains antibodies that make your immune system stronger. It is used for patients who have primary humoral immunodeficiency (PI) ...
For prior biological therapies, eg, monoclonal antibodies with a half-life longer than 3 days, the interval must be at least 28 days prior to the first dose of ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Give by Dec. 3 to double your impact.